Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies

Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies

Source: 
CP Wire
snippet: 
  • Tango will receive $50 million up front
  • The company could receive up to $1.7 billion in additional payments
  • The partnership will focus on building a pipeline of novel immuno-oncology therapies